| The multiple-dose pharmacokinetics of FE 999049 have been described, accounting for endogenous follicle-stimulating hormone (FSH) levels. |
| Exposure to FE 999049 was influenced by body weight, which may be a potential factor for individualised dosing recommendations. |
| Endogenous FSH levels were influenced by progesterone and inhibin B levels. This time-varying contribution of endogenous FSH may be important to consider when characterising the pharmacokinetics of recombinant FSH products. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.